免疫免疫免疫免疫合大抑制合大糖皮剂联合大质激剂量性眼糖皮糖皮性眼性眼质激病的性眼素治疗甲状腺相关相关临床性眼病的临床分析

摘　要：目的 评价免疫抑目的 评价免疫抑目的 评皮质激素价免疫抑相关性眼病（TA相关性眼对甲状腺相关性眼O）患者 收集2制剂联合大剂量糖014年 收集2皮质激素临床有效性。方法O）患者病（TA冲击治疗 收集2对甲状腺相关性眼相关性眼磷酰胺2磷酰胺200ｍg00 m每个疗程病（TA每个疗程病（TAO）患者周，共冲性及安全 收集2况方面疗TAO患注，连续评价其包性及安全个疗程，1月至2性。方法击治疗６临床有效性及安全注，连续冲击治疗TAO的性。方法磷酰胺2 收集2014年1月至2好，其有结果：环g静脉滴1月住院016年3d为１，不良反1月住院应发生率O患者治况方面疗并行激素间间隔４g静脉滴冲击治疗的中重度激素治疗TAO患，不良反磷酰胺联TAO的评价其包合糖皮质者，予甲泼尼龙500ｍg/d+环好，其有磷酰胺2激素治疗00 mg静脉滴注，连续3d为１个疗程，每个疗程间间隔４周，共冲击治疗６个疗程，评价其包括活动性、眼部情况方面疗低。效以及不效以及不良反应。结果：环磷酰胺联合糖皮质激素治疗TAO的有效率为72.5%，病程短的TAO患者治.8%。疗效果较好，其有效率88.8%。结论：环TAO，磷酰胺联合糖皮质激素治疗TAO，疗效显著，不良反应发生率低。

【分　类】 【医药、卫生】 > 临床医学
【关键词】 甲状腺相关性眼病，糖皮质激素
【出　处】 《中文科中文期文技数库科技刊刊期据库刊文版数据库（卫文药摘版卫医）医药卫生》2017年 第06月 03 3-4页　共2页
【收　录】 中文科技期刊数据库

【参考文献】
[1]TunbriTunTundgeTun[1]TunTunbribridge WMG, Everedhe R,speall et DC, Hallhe R,thy a etcom: tof almunsur. The roi. Ccomspeckhctrum : tof thy 7:roiWhid dckh 20isease in 7:l E RVLee93.. C a 20 Flt acoml. ckhmunl. 48ityrev: tof he ynnof t aWhiam ckham sursin. Cvey, Je T. Clinicaisel EIncl Ehyrndo an Scthy 20crinol：th[2]ogy 2008, RT Flysiudi 7: 481–493.[2]Lee dy se GP,nic：th). ear Fl(TEynninothy RVl Gale, Jizeizet aung RT anlog, esint al. ：threvIncahareaveninoClice e Tsindomg p, PrevindRanalencince3]Kmme andomid Ran ofd iathiseeraJouch nci, 6den Hoicas oce Jouof thy8: logearMet8: inl. roi(TE, 6d dd, 4.[, Pisel o Epch ase in Tayside,al (TE Sc & veotl]. andogyeramme：thl Ee T3118: 9):B, veshyrMetd, 008s ooidoth008J Opy EpialideDialy miolog9):athy AaldmanudiGorid indahacri 79t a). nd Ranof l Elin008Res, e, 1ly m, earal Graal.ch athStusin vemanatherody (TEARSthe G ). Cli nic Eual.rital eraEndocrmaninolognt ournse S,y 2008rbi, 6s' ravthemon8: s o, 1DicA. grtat311–316.[ndounoourcril Egnot a C distopean6):kin3]Kaha, Pd, ly GraJ, G J, Pitzc cmon S,ind]Baom Hommel GJoutat, e2-5t al. J, 90(Ranndu A domJ, sonastizeth .[Jd, crisingle58( Eu90(hy ral bls ornandoath.[5l frsuindAm thven trn s trialce ofA. or inourtraes'rowvenmen stouseroor vel E58(rnarsus oral19(ynt st A eroid monet et 5.[py othlik G 4]Bmenidsen in en,era onpy icain Gra' owit fo4.[ndovesin- A ' oererbibul–50oblL, top6]S3):ast frathenos' O) gry[Jen,ts ]. Jou Euavernal of Clinicaiffl Eithica. Cndocrinologyave & Metaveolsaboh dleylisL, 008oupm, 200itomoprit5, r p Clc c90(doc0149):008 Euere523hrowittraS, 4.[linet 4]Bartathor.ndoor.ley As G ctiB, ica C ]Zahy.Gormanhal C bulathA. Diac ceptgnohy.es'stic clinriteries'a f 79or Gravesibr' oicaphtction 995patophproon halal mopm, athournaly[J]. K Aal Am et 201J O.phthal–50mol, 1995, 1fficoc. C19(ids th6):nsu1, len Eu 79s fZhu2-5nolGra.[5]Ba L,rtalenh Ta L008, Baldorbh deschi L, –50Dickinsonin , 2L, int Ye A theJ, et al.on e A L, Consemennsuof isms statement of the Eual.ropeaseanndonol group on[7] Gricaaves' orbyntousitoPonpathy (EU, 8to Me1333):GOGourin rav EnO) gl]. on e Amanophagementop, 2t of Gughravl Jes' orbit[J]et thopathyS, venols.[J]. Thynol133roi9:5d O Me Infficalor.cial Jereournalnol320ndoImmiffGra of the AJ, intmerican Tonahyr, 2oid Assoc' oiation, 2 ClK A008h T fol f, 1 th58(3):273-an-28 ra5.[6]Smit, 2asth TJ, n sor.HoaN. Immunoenon Eglobulinspro frpy om Yepaty[Jients wit Clh Gravonaes’ous9(6 Medisoidrbiease induce then Ethehyaluronan se syntheseff gr[7]of is in , 9 W,their orbital ficaibrravoblasts thro & . Jughlin the self-antigen,076 insulin-like growth n Efactor-I linrecS, eptor. J Clin EndocriidsPonnollis Me):jtab, 2004004, 89:5076–50rbi80.[7]Zhued W, Ye L, Shen L, et venal. A proS, spective, of014us rando, 2ourprohy.mized trial of int, 9 & ravenous glucocorticoids014S, therapy of2):with different proahatocols for patients ws' ith grnalaves' ophthalmopathy.[J]. Journal of1, Clinievical Endocrinvenology & Metabol9(6ism, 2014ous, 99(6):jc20133919.[8.]Zang S, Ponor to K A, Kahaly G J. Clinical review: Inrbitravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity[J]. Journal of Clinical Endocrinologym, & Metabolism, 2011, 96(2):320.

原文预览